Tele-assessment and Face-to-face Assessment of the 30-second Sit-stand Test in Peripheral Artery Disease

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-65
SponsorIzmir Democracy University

About this trial

Peripheral artery disease (PAD) is a chronic and progressive condition caused by narrowing or blockage of arteries in the lower limbs due to atherosclerosis. It primarily affects adults over 50, with prevalence increasing with age, and its clinical presentation ranges from asymptomatic cases to severe ischemia that may require amputation. Intermittent claudication, characterized by exercise-induced leg pain that resolves with rest, is the most common early symptom. Impaired blood flow, poor vascularization, and muscle loss contribute to reduced lower limb strength and functional capacity, which are associated with higher morbidity and mortality.

Walking exercises is a cornerstone of PAD management, particularly for patients with no or mild symptoms, making the assessment of lower limb strength and mobility essential for designing rehabilitation programs. The 30-second sit-to-stand test is a validated and practical measure of functional capacity and walking ability. Tele-assessment using video technology has been shown to be feasible and reliable in other patient populations. Although tele-rehabilitation has been widely studied and shown to improve functional outcomes, research on tele-assessment methods to accurately evaluate patient performance and the effectiveness of rehabilitation programs is still limited, particularly in PAD patients.

This study aims to examine the reliability of the 30-second sit-to-stand test when performed via tele-assessment compared with face-to-face evaluation in patients with PAD.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Aged between 18 and 65 years

Diagnosed with peripheral artery disease, Fontaine stage I-II, confirmed by peripheral angiography or Doppler ultrasonography

Willingness to participate in the study

Access to a smartphone and the internet

Disqualifiers

Presence of orthopedic, neurological, or psychological conditions that limit physical activity

Neurological or musculoskeletal disorders affecting standing or walking

History of ischemic amputation

Acute inflammatory condition

Trial population

Patients diagnosed with peripheral artery disease, aged 18 to 65 years.

Trial design

Design model

Cohort

Time perspective

Cross-sectional

Treatments tested in this trial

Not listed

Trial groups

45 Participants
are grouped into 1 trial group
Group A: Peripheral Arterial Disease

Trial outcomes

Primary outcomes

1

Lower Extremity Function

Lower extremity strength and functional mobility will be evaluated using the 30-second sit-to-stand test. Participants will sit on a 44 cm high chair with a backrest and no armrests, arms crossed over the shoulders, and will be instructed to stand and sit as many times as possible within 30 seconds. The number of complete repetitions will be recorded.

Time frame
From February 2026 to June 2026

Secondary outcomes

1

Perceived Fatigue Response to 30 Second Sit-to-Stand Test

Perceived fatigue will be measured before, immediately after, and at 3 minutes of recovery following the sit-to-stand test using the Modified Borg Scale.

Time frame
February 2026 to June 2026
2

Dyspnea Response to 30 Second Sit-to-Stand Test

Dyspnea severity will be assessed before, immediately after, and at 3 minutes of recovery following the sit-to-stand test using the Modified Borg Scale.

Time frame
February 2026 to June 2026
3

Heart Rate Response to 30 Second Sit-to-Stand Test

Heart rate will be measured before, immediately after, and at 3 minutes of recovery following the sit-to-stand test using a pulse oximeter.

Time frame
February 2026 to June 2026
4

Blood Pressure

Systolic and diastolic blood pressure will be measured before, immediately after, and at 3 minutes of recovery following the sit-to-stand test.

Time frame
February 2026 to June 2026

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.